Page 262 - The Vasculitides Volumes 2

238 Antoine Sreih and Peter A. Merkel

[25] Mukhtyar, C., Guillevin, L., Cid, M. C., et al. EULAR recommendations for the
management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 2009;
68:310-317.

[26] Stone, J. H., Merkel, P. A., Spiera, R., et al. Rituximab versus cyclophosphamide for
ANCA-associated vasculitis. N. Engl. J. Med. 2010; 363:221-232.

[27] Jones, R. B., Tervaert, J. W., Hauser, T., et al. Rituximab versus cyclophosphamide in
ANCA-associated renal vasculitis. N. Engl. J. Med. 2010; 363:211-220.

[28] De Groot, K., Harper, L., Jayne, D. R. W., et al. Pulse versus daily oral
cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-
associated vasculitis. Ann. Int. Med. 2009; 150:670-680.

[29] De Groot, K., Adu, D., Savage, C. O., et al. The value of pulse cyclophosphamide in
ANCA-associated vasculitis: meta-analysis and critical review. Nephrol. Dial.
Transplant. 2001; 16:2018-2027.

[30] Jayne, D., Rasmussen, N., Andrassy, K., et al. A randomized trial of maintenance
therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N.
Engl. J. Med. 2003; 349:36-44.

[31] De Groot, K., Rasmussen, N., Bacon, P. A., et al. Randomized trial of
cyclophosphamide versus methotrexate for induction of remission in early systemic
antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheum. 2005; 52:
2461-2469.

[32] Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus
standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 2005 Jan. 27; 352:
351-361.

[33] Pagnoux, C. Mahr, A., Hamidou, M. A., et al. Azathioprine or methotrexate
maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 2008 25; 359:2790-
2803.

[34] Hiemstra, T. F., Walsh, M., Mahr, A., et al. Mycophenolate mofetil vs azathioprine for
remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis.
JAMA 2010; 304:2381-2388.

[35] Cartin-Ceba, R. Golbin, J. M., Keogh, K. A., et al. Rituximab for remission induction
and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year
experience at a single center. Arthritis Rheum. 2012; 64:3770-3778.

[36] Smith, R. M. Jones, R. B., Guerry, M. J., et al. Rituximab for remission maintenance in
relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum.
2012; 64:3760-769.

[37] Jayne, D. R., Gaskin, G., Rasmussen, N., et al. Randomized trial of plasma exchange or
high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J.
Am. Soc. Nephrol. 2007; 18:2180-2188.

[38] Walsh, M., Catapano, F., Szpirt, W., et al. Plasma exchange for renal vasculitis and
idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am. J. Kidney Dis.
2011; 57:566-574.

[39] Walsh, M., Merkel, P. A., Peh, C. A., et al. Plasma exchange and glucocorticoid dosing
in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis
(PEXIVAS): protocol for a randomized controlled trial. Trials 2013; 14:73.

[40] Jayne, D. R., Chapel, H., Adu, D., et al. Intravenous immunoglobulin for ANCA-
associated systemic vasculitis with persistent disease activity. QJM 2000; 93:433-439.

Complimentary Contributor Copy